-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Neutral on ADMA Biologics, Raises Price Target to $13

Benzinga·11/05/2026 09:40:43
Listen to the news
Cantor Fitzgerald analyst Kristen Kluska maintains ADMA Biologics (NASDAQ:ADMA) with a Neutral and raises the price target from $12 to $13.